Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galangin is a natural flavonol—specifically, a 3,5,7-trihydroxyflavone—found in high concentrations in the rhizomes of Alpinia officinarum (lesser galangal), Alpinia galanga, propolis, and some other plants[1][6]. It exhibits a range of biological activities, including anti-inflammatory, antioxidant, antiviral, antibacterial, and anticancer effects demonstrated in preclinical models[6][7][5]. Mechanistic studies show galangin inhibits cell proliferation and induces apoptosis in cancer cells, in part by modulating the JAK2/STAT3/ROS signaling pathway[5]. Additionally, galangin displays antinociceptive (pain-relieving) action mediated by modulation of opioid receptors, vanilloid (TRPV1) receptors, and the glutamatergic system, and it reduces pro-inflammatory cytokines such as IL-1β, TNF-α, and IFN-γ in animal models[3]. Galangin is a small molecule with rapid absorption and elimination profiles when administered orally or intraperitoneally in rodents, but its low bioavailability has prompted investigation into advanced delivery systems such as liposomes, micelles, nanostructured lipid carriers, and β-cyclodextrin complexes for enhanced therapeutic efficacy[1]. It is not an approved pharmaceutical and is primarily researched as a bioactive dietary flavonoid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galangin.